The European Commission (EC) has approved the extension of indication for Janssen-Cilag International’s Darzalex (daratumumab) subcutaneous (SC) formulation to be used in the frontline setting ...

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a longer progression free survival for patients with newly diagnosed ...

That alliance also generated Darzalex (daratumumab) – Janssen's $4.1 billion myeloma blockbuster – as well as Rybrevant (amivantamab), its first bispecific which has been approved to treat ...

announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission approval for an indication extension of DARZALEX, or daratumumab, subcutaneous co ...

Professor Katja Wesel, University Medical Centre Hamburg-Eppendorf, has provided consulting, advisory, and speaking services to Janssen; she has not been paid for any media work. [i] European ...

Both Janssen's marketing applications are based ... after drugs like J&J's anti-CD38 antibody Darzalex (daratumumab) as well as proteasome inhibitors such as Takeda’s Velcade (bortezomib ...

Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received European Commission approval for an ...

Inc. (Janssen) an exclusive worldwide license to develop, manufacture and commercialize daratumumab. “AL amyloidosis is a potentially fatal blood disorder for which there is no cure, so we are ...

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody ...